Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 26, 2017
What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?
BRISTOL MYERS SQUIBB has seventy-seven approved drugs.| Patents: | 18 |
| Tradenames: | 66 |
| Ingredients: | 58 |
| NDAs: | 77 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
apixaban | Tablets | 2.5 mg and 5 mg | ELIQUIS | 12/28/2016 |
naloxone hydrochloride | Nasal Spray | 4 mg/spray | NARCAN | 7/15/2016 |
dasatinib | Tablets | 80 mg and 140 mg | SPRYCEL | 6/17/2011 |
dasatinib | Tablets | 80 mg and 140 mg | SPRYCEL | 6/16/2011 |
dasatinib | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | SPRYCEL | 6/28/2010 |
entecavir | Tablets | 0.5 mg and 1 mg | BARACLUDE | 6/14/2010 |
atazanavir sulfate | Capsules | 100 mg and 150 mg | REYATAZ | 3/19/2010 |
atazanavir sulfate | Capsules | 200 mg | REYATAZ | 2/16/2010 |
atazanavir sulfate | Capsules | 300 mg | REYATAZ | 7/20/2009 |
efavirenz | Tablets | 600 mg | SUSTIVA | 4/9/2009 |
pravastatin sodium | Tablets | 30 mg | PRAVACHOL | 6/1/2005 |
didanosine | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | VIDEX EC | 6/1/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,691,846 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| 6,110,946 | Antivirally active heterocyclic azahexane derivatives | ► Subscribe | |||||||||||||
| 8,470,854 | Lactam-containing compounds and derivatives thereof as factor XA inhibitors | ► Subscribe | |||||||||||||
| 7,091,223 | Cyclic protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||
| 7,189,854 | Cyclic protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||
| 6,979,694 | Cyclic protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||
| RE38629 | Solid oral dosage form comprising a combination of metformin and glibenclamide | ► Subscribe | |||||||||||||
| 7,371,761 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| 6,300,519 | Antivirally active heterocyclic azahexane derivatives | ► Subscribe | |||||||||||||
| 7,960,411 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Denmark | 1427415 | ► Subscribe | |||||||||||||
| Poland | 193822 | ► Subscribe | |||||||||||||
| Slovakia | 284655 | ► Subscribe | |||||||||||||
| Hungary | S1300014 | ► Subscribe | |||||||||||||
| African Regional IP Organization (ARIPO) | 200001885 | ► Subscribe | |||||||||||||
| European Patent Office | 1056722 | ► Subscribe | |||||||||||||
| African Regional IP Organization (ARIPO) | 1450 | ► Subscribe | |||||||||||||
| Canada | 2519898 | ► Subscribe | |||||||||||||
| China | 1193010 | ► Subscribe | |||||||||||||
| Japan | 2002509136 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0006 | France | ► Subscribe | PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728 | ||||||||||||
| 11/024 | Ireland | ► Subscribe | PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923 | ||||||||||||
| 888 | Luxembourg | ► Subscribe | 91888, EXPIRES: 20260518 | ||||||||||||
| 00492 | Netherlands | ► Subscribe | PRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921 | ||||||||||||
| C/GB08/033 | United Kingdom | ► Subscribe | PRODUCT NAME: TENOFOVIR DISOPROXIL AND THE SALTS (IN PARTICULAR THE FUMARATE), HYDRATES, TAUTOMERS AND SOLVATES THEREOF, TOGETHER WITH EMTRICITABINE AND EFAVIRENZ; REGISTERED: UK EU/1/07/430/001 20071213; REASON FOR LAPSE: SURRENDERED | ||||||||||||
| 146 | Luxembourg | ► Subscribe | PRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES | ||||||||||||
| 90029-7 | Sweden | ► Subscribe | PRODUCT NAME: APIXABAN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/11/691/001-005 20110518 | ||||||||||||
| C0021 | France | ► Subscribe | PRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213 | ||||||||||||
| 2011012,C1427415 | Lithuania | ► Subscribe | PRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518 | ||||||||||||
| 1214076/01 | Switzerland | ► Subscribe | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,771 others who get our Drug Patent Expiration Alerts:
